Recent advances in the synthesis of endocannabinoidrelated ligands for the period 2001-2004 are covered in this review. During this period the fi rst solid phase synthesis of anandamide (AEA) analogs was developed, which allows modifi cation at both the head group and the end pentyl chain. Synthesis of water-soluble prodrugs of noladin ether was reported, which are chemically stable, rapidly release noladin ether under enzymatic conditions and are shown to reduce intraocular pressure. The structure-activity relationships (SAR) of alkylcarbamic acid aryl esters and the discovery of potent archidonylsulfonyl derivatives as fatty acid amide hydrolase (FAAH) inhibitors are summarized. Recent synthetic developments in the controversial area of anandamide membrane transporter (AMT) inhibitors are also discussed.
INTRODUCTION
The past decade has seen a sudden spurt of interest in the cannabinoid fi eld. [1] [2] [3] [4] [5] Two types of cannabinoid receptors have been discovered: the CB1 receptor located both inside and outside the central nervous system (CNS), and the CB2 receptor located mainly in the periphery. 6 , 7 The CB1 receptor has been established to be a G-protein-coupled receptor. The fi rst potent CB1 receptor antagonist SR141716A was reported by Rinaldi-Carmona et al, 8 who also reported the CB2 selective receptor antagonist SR144522. 8 , 9 Anandamide (AEA) was identifi ed as the endogenous ligand for the CB1 receptor. Another important endogenous ligand is 2-arachidonyl-glycerol (2-AraGl), which activates both CB1 and CB2 receptors. Both AEA and 2-Ara-Gl are found together with a family of related fatty acid glycerol esters and fatty acyl ethanolamides. It was found that the potency of 2-Ara-Gl was enhanced in the presence of the related 2-acyl-glycerols. This effect has been termed the " entourage effect," which probably represents the pathway for molecular regulation of endogenous cannabinoid activity. 10 Hanus et al 11 iso lated yet another endogenous ligand "noladin ether" (2-arachidonylglyceryl ether) from porcine brain. 11 It binds to CB1 receptors and very weakly to CB2 receptors. During this review period 2 other endocannabinoids, virodhamine and N-arachidonyl dopamine, were discovered. 12 , 13 Virodhamine was found to be a CB1 receptor antagonist and partial agonist of CB2 receptor and N-arachidonyl dopamine was CB1 selective and also active at vanilloid VR1 receptors. The pharmacological activities of D 9 -tetrahydrocannabinol (D 9 -THC) and the endogenous ligand AEA are alike, however the onset of action of AEA is much faster and the duration of action is much shorter compared with D 9 -THC. This has been attributed to the enzymatic hydrolysis of the amide bond in AEA; the enzyme involved in the metabolic degradation of AEA has been characterized as "fatty acid amide hydrolase" (FAAH). Several metabolically stable analogs of AEA have been synthesized that have greater binding affi nities than AEA. 14 , 15 Makriyannis and coworkers 15 have improved the metabolic stability of the AEA part by incorporation of the methanandamide head group; our group has enhanced the metabolic stability by introduction of substituents on the carbon in the 2-position of the ara chidonic acid part of AEA. AEA is produced from phos pholipid precursors and it has been proposed that for its termination AEA is carried into the neurons by the anandamide membrane transporter (AMT) and then undergoes enzymatic hydrolysis into AEA and ethanolamine. The synthetic approaches to ligands that are associated with the endocannabinoid system, eg, AEA, 2-Ara-Gl, noladin ether, FAAH and AMT, have been discussed in detail in our previous review. 16 In this article we will be covering the chemistry and SAR, which have been developed subsequently in the above-mentioned areas.
AEA AND 2-ARA-GL ANALOGS
The structures of AEA and 2-Ara-Gl are shown in Figure 1 . The ethanol amine group is described as the head group moiety a ; the arachidonyl backbone is moiety b ; and the end pentyl chain is moiety c . During this period, no new chemistry was described related to either the head group (moiety a ) or the arachidonyl backbone (moiety b ). Only a new route was described for the introduction of different substituents in moiety c . 17 described a fl exible route to the synthesis of AEA analogs with modifi cations in the end pentyl chain, which is moiety c . The key step in the strategy involves copper-catalyzed coupling of the bromo intermediate 1 ( Figure 2 ) with the appropriate acetylenic derivatives. The target amides in the AEA series were synthesized by hydrolysis of the esters 2a-d ( Figure 2 ) to the acids using LiOH, followed by their conversion to the corresponding acid chloride and coupling with (R)-2-aminopropanol. Alternatively, the target amides in this series were also synthesized by the mixed anhydride procedure. The SAR studies of these compounds have not yet been published.
An important development is the report by Qi et al 18 on the fi rst solid phase synthesis of AEA analogs. The synthetic route ( Figure 3 ) is very versatile and it involves attachment of 5-hexynoic acid to Wang resin via an ester linkage followed by repetitive copper-catalyzed coupling with propargylic alcohols to provide the tetrayne skeleton. Cleavage of the tetrayne was accomplished by treatment with TFA or AlMe 3 /amine to furnish the corresponding acids and amides, respectively, which was then reduced with P-2 Ni as the catalyst to furnish the desired products. Advantages of this procedure are that it allows modifi cations at both the head group moiety a and the end pentyl chain moiety c and thus allows for the effective synthesis and SAR of several modifi ed AEA analogs.
To examine the SAR in the arachidonyl alcohol series, Parkkari et al 19 synthesized several ester, carbonate, and carbamate derivatives of arachidonyl alcohol. The major hurdle that they encountered in the synthesis of archidonyl alcohol esters was its self-degradation and polymerization. In general, the synthesis of these analogs was accomplished by dicyclohexylcarbodiimide (DCC) coupling of the appropriate acid partners with arachidonyl alcohol. The silyl protecting groups, which were used to protect the alcohols, were deprotected using tetrabutyl ammonium fl uoride (TBAF) in tetrahydrofuran (THF). The carbonates and the carbamates were synthesized via p-nitro-phenylchloroformate-activated intermediates as shown in Figure 4 . The results obtained from their SAR study indicate that among the different analogs that were tested only the ester analogs 3a and 3b ( Figure 4 ) showed some activity at the CB1 receptor, however even these compounds were found to be less potent and effi cacious when compared with AEA.
Fangour et al 20 synthesized analogs based on 2-Ara-Gl and AEA template ( Figure 5 ) where one hydroxymethylene group of the glycerol moiety was replaced with hydrogen to give compound 7a . The stability of the ester analog was improved by introduction of substituents on the carbon in the 2-position of the arachidonic acid part to give compound 6 . They also prepared the methylene-linked analog of AEA 
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compound 7b where the amide bond of AEA was replaced by a ketone functionality. The synthesis of the ketone analog 7b was accomplished by treatment of Weinreb amide of arachidonic acid with the lithiated anion 8 to give the compound in an overall 27% yield. The analogs 6 and 7a were prepared by standard procedures. 14 The affi nity of these compounds for the CB1 receptor was investigated and it was found that the ketone analog 7b showed moderate binding affi nity (binding affi nity [K i ] = 360 nM) to CB1 receptor, while the other two compounds 6 and 7a were found to be inactive.
NOLADIN ETHER
To increase the metabolic stability of 2-Ara-Gl, Mechoulam's group 14 synthesized noladin ether and it was later isolated from porcine brain as an endogenous cannabinoid ligand. To improve the aqueous solubility properties of these lipophilic compounds, Juntunen et al 21 synthesized watersoluble prodrugs of noladin ether. Monophosphate and diphosphate esters of noladin ether 9 and 10 ( Figure 6 ) were synthesized by treatment of noladin ether with dimethylchloro phosphate in the presence of pyridine as base. Juntunen et al found that both compounds 9 and 10 showed good chemical stability in buffer solutions at pH 7.4 and were also more soluble in aqueous solutions (>40 000-fold) when compared with noladin ether. These compounds rapidly converted into noladin ether under enzymatic hydrolysis conditions and the monophosphate ester 9 was able to reduce intraocular pressure in normotensive rabbits.
FAAH INHIBITORS
A detailed discussion of the synthetic approaches and SAR of various classes of FAAH inhibitors can be found in our previous review. 16 Since then, the synthesis and SAR of alkylcarbamic acid aryl esters as FAAH inhibitors has been reported by Tarzia et al 22 and Mor et al. 23 One of the potent analogs, URB524, displayed profound anxiolytic-like properties in rats. The design of the alkylcarbamic acid aryl esters were based on the structural modifi cations of the known inhibitor of serine hydrolase acetylcholine esterase compound 11 ( Figure 7 ) . In general these compounds were synthesized by addition of the appropriate alcohols or amines to isocyanatocyclohexane in the presence of triethyl amine as base. A brief summary of the SAR of this class of inhibitors is given below.
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1. Replacement of the methyl group in 12 with the cyclohexyl group gave compound 13, which showed a 60-fold improvement in inhibitor potency.
2 . Modifi cation of the carbamate function was found to be detrimental to its FAAH inhibitory activity. Ester and urea analogs were found to be inactive and replacement of the oxygen with sulfur to give the thiocarbamic acid derivatives was also found to be inactive.
3. Based on conformational analysis, Tarzia et al hypothesized that the shape of the aromatic substituent on the oxygen atom might be critical. Hence, they synthesized a series of analogs with different aromatic substituents in which they tried to mimic the "U-shaped" conformation of the fatty acid chain of AEA. The best inhibitor in this series was found to be URB524 (Inhibitor Potencies [IC 50 ] = 63 nM).
4 . Modifi cations in which the aromatic substituents were replaced by alkyl chains were also found to be detrimental to the activity. Reversing the groups on the N-and O-substituents of URB524 gave compound 14, which was found to be an inactive compound.
5 . SAR was then conducted based on the structural template of URB524. The most potent compound in the series was URB597 (IC 50 = 4.6 nM), which has a substituent in the meta position of the distal phenyl ring. The meta-substituted compounds were in general found to be more active than the E500 corresponding para isomers, for example compound 15 has an IC 50 = 5909 nM.
Arachidonylsulfonyl derivatives 16 and 17 ( Figure 8 ) were reported by Segall et al 24 as novel inhibitors of FAAH with the potency of 16 being similar to methyl arachidonyl-fl uorophosphonate. The synthesis involves conversion of arachidonyl bromide into arachidonylsulfonyl chloride via Grignard reaction. Subsequent treatment of arachidonylsulfonyl chloride with tetrabutylammonium fl uoride and ethanolamine provided compounds 16 and 17 respectively.
AMT TRANSPORTER INHIBITORS
A comprehensive review of AMT inhibitors and their potential as drugs for CNS-related disorders was recently reported by Lopez-Rodriguez and Ortega-Gutierrez. 25 However, the AMT protein has not been isolated or cloned and the whole issue of AMT has since become controversial. Nevertheless, Di Marzo et al 26 synthesized a series of AMT transporter inhibitors based on arachidonyl 18b and oleoyl templates 18a ( Figure 9 ) where the head group moiety a contains different aromatic moieties. Their design is based on the observation that AMT transporter inhibitors, which have been designed to date, all contain aromatic moieties in the polar head group region. In general, the synthesis of these compounds has been accomplished by N-ethyl-N′-(3-dimethylamino propyl)
carbodiimide (EDCI) coupling of the appropriate acids and amines to yield the desired products in good yields. The results obtained from their SAR study are summarized below.
1. Comparison of the arachidonyl template b and oleoyl template a show that the most potent and selective inhibitors in this series ( 19a , X=H K i = 12.9 mM; 20a K i = 6.4 mM) have the oleoyl template.
2. Deletion of the phenolic hydroxyl from compounds 18a and 18b (for 18a X = OH, K i = 3.0 mM vs X = H, K i = 11.1 mM) results in a decrease in the affi nity for AMT. An opposite effect is seen in the compounds with general structure 19 . In the series of compounds with general structure 20 the (S,S)-diasteromer of oleic acid series shows an appreciable increase in activity with introduction of the hydroxyl group, however the trend is reversed in the arachidonic acid series where the (R,R)-diastereomer shows increase in activity.
3. Next, the restriction of the hydroxyalkyl group was investigated and it was observed that the conformationally restricted analogs 21 (both R and S) were found to be completely inactive.
Lopez-Rodriguez et al 27 synthesized a series of esters and amides with the general structural template 22 ( Figure 10 ) and explored the structure-affi nity relationship between 22 and AMT. The compounds were synthesized from arachidonic acid by conversion to the acid chloride and coupling with the appropriate amine or alcohol or by direct DCC coupling of arachidonic acid with the appropriate amine or alcohol. From the results obtained, they concluded that there is no correlation between the effects on FAAH and on AMT. Compound 23 is a more potent FAAH inhibitor than 
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compound 24 , however it is found to be inactive as an AMT inhibitor. Compounds 24 to 27 display similar FAAH inhibitory potencies, but differ in their ability to inhibit anandamide uptake (IC 50 range from 0.8 to 26 mM). The most potent AMT inhibitor in this series is compound 24, which is selective (CB1 K i = 4700 nM; CB2 K i = 67 nM; VR1 K i > 5000 nM) except for moderate binding affi nity to the CB2 receptor.
CONCLUSIONS
Since the discovery of the fi rst endocannabinoids, anandamide and 2-arachidonyl glycerol, other endocannabinoids have been discovered, the pathway to their biosynthesis and degradation has been elucidated, and, as a result, the role of endocannabinoids in the brain has been fi rmly established. Progress is being made in understanding the full implications of their presence in the brain and the periphery, which may lead to the development of novel therapies in medicine.
